The first 266,000 flu vaccines manufactured by Sanofi have passed state quality control and are being distributed to pharmacies and medical facilities.
According to the Ministry of Health, three batches of the vaccine have received a positive assessment from the Ukrainian Agency for Medicines and Medical Devices.
In addition, a flu vaccine manufactured in South Korea is currently undergoing laboratory testing. It is planned that 140,000 doses of this vaccine will enter the Ukrainian market in the near future, following approval by state authorities.
As previously reported, 406,000 doses of flu vaccine were expected to be delivered during the current flu season; deliveries are scheduled for November—140,000 doses of GC Flu vaccine manufactured by GC Biopharma Corp. (South Korea), imported by Biolabs LLC, and 266,000 doses of the Vaxigrip vaccine manufactured by Sanofi-Inotrop Industries (France), imported by Sanofi-Aventis Ukraine LLC.
During the 2025–2026 flu season, 136,000 doses of the GC Flu vaccine and 100,670 doses of Vaxigrip Tetra passed state quality control.
A year earlier, during the 2024–2025 flu season, approximately 370,000 doses of flu vaccines were delivered to Ukraine (250,000 doses of Vaxigrip Tetra and 120,000 doses of GC Flu). According to a representative of the GC Flu importer, approximately one-third of the Korean vaccine had to be disposed of due to low demand.
